Events

Stay informed about how NOCITA® (bupivacaine liposome injectable suspension) can help your canine patients following cranial cruciate ligament surgery.

Upcoming Webinar

Join us each month for a 60-minute webinar on the latest in post-operative treatment advances, including a live Q&A session.

Wednesday, October 25, 2017

To register and join the webinar, please click below.

Past Webinars

Learn more about NOCITA on your own schedule. View presentations by your peers regarding the latest methods in canine perioperative pain control.

*Continuing education accreditation provided for live-events only. Previously recording webinars are not RACE approved for CE.

Conferences

Find NOCITA at an Aratana booth during these upcoming conferences.

IVECCS 2017

At the International Veterinary Emergency and Critical Care Symposium (IVECCS) in Nashville, Aratana will showcase NOCITA® (bupivacaine liposome injectable suspension), a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs.

 

On Saturday, September 16, the Company is holding a breakfast session (6:30 -7:30 a.m.) featuring an interactive roundtable discussion with Kristin Kirkby-Shaw, DVM, MS, PhD, DACVS, DACVSMR, Andrew Jackson, DVM, DACVS and Bonnie Wright, DVM, DACVAA. The panel will detail how they have successfully incorporated NOCITA into their practice protocols and take questions from session attendees.

 

IVECCS attendees should consider participating in the Aratana sponsored full-day dry lab, “Basic and Advanced Regional Anesthesia,” instructed by Dr. Gregg Griffenhagen, DVM, DACVAA. Additionally, visit the Aratana booth to take advantage of exciting show specials on NOCITA and register to win an Apple® watch!

 

IVECCS Conference Link >

ACVS 2017

Aratana will continue showcasing NOCITA® (bupivacaine liposome injectable suspension), a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs, at the American College of Veterinary Surgeons (ACVS) Surgery Summit in Indianapolis.

 

Aratana will host a NOCITA lunch session (12:15 -1:15 p.m.) on Friday, October 13 with Kristin Kirkby-Shaw, DVM, MS, PhD, DACVS, DACVSMR, Andrew Jackson, DVM, DACVS and Bonnie Wright, DVM, DACVAA participating in an interactive roundtable discussion on NOCITA, specifically detailing how they have successfully incorporated the long-acting local analgesic into practice protocols.

 

Aratana will also sponsor the “Anesthesia and Pain Management” full-day CE track led by Sandra Perkowski, VMD, PhD, DACVAA and Brain Trumpatori, DVM, DACVS-SA. Attendees are also encouraged to visit with Aratana at the booth to learn about show specials on NOCITA and register to win an Apple® watch!

 

ACVS Conference Link >

Wet Labs and Educational Courses

See NOCITA in action as veterinarians lead hands-on surgical sessions aided by cutting-edge pain management.

MWI Securos Surgical – Comprehensive Extracapsular Stifle Stabilization Course

These courses are designed for the veterinarian who wishes to learn/refine the lateral suture technique. These courses include a comprehensive discussion of the biomechanics of the lateral suture technique, preoperative planning techniques, post-operative pain management and how best to prevent and treat post-operative complications. The lateral suture technique will be taught in a step-by-step fashion with the assistance of intraoperative videos and practiced on canine cadavers.

 

March 12, 2017 – Denver, CO

April 30, 2017 – Houston, TX

August 27, 2017 – Boston, MA

October 15, 2017 – Chicago, IL

 

Learn more >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

ENTYCE logo

 

ENTYCE (capromorelin oral solution) provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE provides safe, effective appetite stimulation.

VIEW WEBSITE

 

 

 

 

 

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

GALLIPRANT logo

 

GALLIPRANT® (gapriprant tablets)
for the control of pain and inflammation associated with osteoarthritis in dogs.

GALLIPRANT is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.1

1Kirkby Shaw K, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.


In co-promotion with Elanco

VIEW WEBSITE

 

 

IMPORTANT SAFETY INFORMATION: Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If GALLIPRANT is used long term, appropriate monitoring is recommended. Concomitant use of GALLIPRANT with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of GALLIPRANT has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the full Prescribing Information for more detail.